2024
PPAR-Mediated Bile Acid Glucuronidation: Therapeutic Targets for the Treatment of Cholestatic Liver Diseases
Gallucci G, Hayes C, Boyer J, Barbier O, Assis D, Ghonem N. PPAR-Mediated Bile Acid Glucuronidation: Therapeutic Targets for the Treatment of Cholestatic Liver Diseases. Cells 2024, 13: 1296. PMID: 39120326, PMCID: PMC11312002, DOI: 10.3390/cells13151296.Peer-Reviewed Original ResearchPrimary biliary cholangitisPrimary sclerosing cholangitisPeroxisome proliferator-activated receptorCholestatic liver diseaseUrsodeoxycholic acidUridine 5'-diphospho-glucuronosyltransferaseObeticholic acidBile acid metabolismAdjunctive therapyIncomplete response to UDCAProgression of primary biliary cholangitisResponse to UDCALiver diseasePeroxisome proliferator-activated receptor agonistsSecond-line treatmentMarkers of cholestasisImpairment of bile flowTherapeutic targetTreatment of cholestatic liver diseasesRetention of bile acidsAlternative treatment strategiesProgression to fibrosisProliferator-activated receptorsAcid metabolismBiliary cholangitis
2022
Fenofibrate Downregulates NF-κB Signaling to Inhibit Pro-inflammatory Cytokine Secretion in Human THP-1 Macrophages and During Primary Biliary Cholangitis
Gallucci GM, Alsuwayt B, Auclair AM, Boyer JL, Assis DN, Ghonem NS. Fenofibrate Downregulates NF-κB Signaling to Inhibit Pro-inflammatory Cytokine Secretion in Human THP-1 Macrophages and During Primary Biliary Cholangitis. Inflammation 2022, 45: 2570-2581. PMID: 35838934, PMCID: PMC10853883, DOI: 10.1007/s10753-022-01713-1.Peer-Reviewed Original ResearchConceptsPrimary biliary cholangitisPrimary sclerosing cholangitisAnti-inflammatory mechanismsChronic liver diseaseNF-κB signalingBiliary cholangitisLiver diseaseNF-κB p50IL-1βIL-8Peroxisome proliferator-activated receptor alphaPro-inflammatory cytokine secretionProliferator-activated receptor alphaIncomplete biochemical responseAnti-inflammatory effectsAddition of fenofibratePro-inflammatory cytokinesPPARα-dependent mannerHuman THP-1 macrophagesP65 protein expressionLabel therapeutic optionTHP-1 macrophagesTHP-1 cellsSclerosing cholangitisAdult patients
2020
A Systematic Review of Patient‐Reported Outcomes in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis
Kim HP, Lieber SR, Rogers ME, Moon AM, Loiselle M, Walker J, Assis DN, Safer R, Gomel R, Evon DM. A Systematic Review of Patient‐Reported Outcomes in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis. Hepatology Communications 2020, 4: 1502-1515. PMID: 33024919, PMCID: PMC7527768, DOI: 10.1002/hep4.1567.Peer-Reviewed Original ResearchPrimary biliary cholangitisPrimary sclerosing cholangitisHealth-related qualityPRO instrumentsPRO conceptsSclerosing cholangitisAdverse eventsBiliary cholangitisSystematic reviewDecreased health-related qualityPhysical adverse eventsGastrointestinal adverse eventsNumeric rating scaleTarget populationStudy populationVisual analogueCholangitisPatient experiencePsychometric testingPatient validationStudy outcomesRating ScaleDescriptive statisticsOutcome conceptsOutcomesFenofibrate Improves Liver Function and Reduces the Toxicity of the Bile Acid Pool in Patients With Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Who Are Partial Responders to Ursodiol
Ghonem NS, Auclair AM, Hemme CL, Gallucci GM, de la Rosa Rodriguez R, Boyer JL, Assis DN. Fenofibrate Improves Liver Function and Reduces the Toxicity of the Bile Acid Pool in Patients With Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Who Are Partial Responders to Ursodiol. Clinical Pharmacology & Therapeutics 2020, 108: 1213-1223. PMID: 32480421, PMCID: PMC7886378, DOI: 10.1002/cpt.1930.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBile Acids and SaltsBiomarkersCholangitis, SclerosingCytokinesDrug Therapy, CombinationFemaleFenofibrateHumansInflammation MediatorsLiverLiver Cirrhosis, BiliaryLiver Function TestsMaleMiddle AgedPPAR alphaPrincipal Component AnalysisRetrospective StudiesTreatment OutcomeUrsodeoxycholic AcidYoung AdultConceptsPrimary sclerosing cholangitisPrimary biliary cholangitisBile acid metabolismSclerosing cholangitisBiliary cholangitisBile acidsAcid metabolismPeroxisome proliferator-activated receptor alphaProliferator-activated receptor alphaRetrospective observational studyBeneficial clinical effectsCholestatic liver diseasePro-inflammatory cytokinesBile acid metabolitesHealthy control subjectsBile acid poolSerum alkaline phosphataseAminotransferase abnormalitiesUrsodiol therapyFenofibrate therapyPartial respondersBile acid precursorsClinical effectsFenofibrate treatmentLiver disease
2019
2797 Fenofibrate and PSC: A Case Series From a Single Center Liver Registry
Shah S, Silveira M, Assis D, Cusack L. 2797 Fenofibrate and PSC: A Case Series From a Single Center Liver Registry. The American Journal Of Gastroenterology 2019, 114: s1544-s1545. DOI: 10.14309/01.ajg.0000600720.33625.bb.Peer-Reviewed Original ResearchPrimary sclerosing cholangitisPrimary biliary cholangitisCase seriesUrsodeoxycholic acidLarge-duct primary sclerosing cholangitisTreatment of primary sclerosing cholangitisNo current effective therapyRetrospective single-center case seriesPrimary sclerosing cholangitis patientsSingle-center case seriesAlkaline phosphataseRisk scorePrimary sclerosing cholangitis treatmentPost-FFSAlkaline phosphatase reductionPatients due to lackAcute kidney injuryCholestatic liver diseaseAlkaline phosphatase levelsCurrent effective therapiesSerum alkaline phosphataseInflammatory bowel diseaseIntrahepatic diseaseAutoimmune hepatitisRecurrent cholangitis
2018
Chronic Complications of Cholestasis Evaluation and Management
Assis DN. Chronic Complications of Cholestasis Evaluation and Management. Clinics In Liver Disease 2018, 22: 533-544. PMID: 30259851, DOI: 10.1016/j.cld.2018.03.014.BooksMeSH KeywordsAbsorptiometry, PhotonAvitaminosisBone Density Conservation AgentsBone Diseases, MetabolicCarcinoma, HepatocellularCholestasisDiet, HealthyEarly Detection of CancerEsophageal and Gastric VaricesExerciseFibric AcidsGastrointestinal HemorrhageHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHyperlipidemiasHypertension, PortalLiver Cirrhosis, BiliaryLiver NeoplasmsMass ScreeningOsteoporosisOsteoporotic FracturesVitamin A DeficiencyVitamin D DeficiencyVitamin E DeficiencyVitamin K DeficiencyConceptsPrimary biliary cholangitisChronic cholestasisFat-soluble vitamin deficiencyEarly-stage diseaseMetabolic bone diseaseCardiovascular eventsChronic complicationsPortal hypertensionBiliary cholangitisVitamin deficiencyBone diseaseLong-term effectsNotable riskCholestasisComplicationsPatientsPractical managementDiseaseRiskHarmful consequencesCholangitisHypertensionHyperlipidemiaOsteoporosisTherapy